ABBV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

16.39B

+8.54%

3.353

+55.24%

14.74B

+10.45%

3.112

+26.5%

16.57B

+7.42%

3.639

+22.53%

Estimates Revision

The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by -1.67%.

Revenue Estimates for FY2025

Revise Upward

+0.44%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.43%

In Past 3 Month

Stock Price

Go Down

-1.67%

In Past 3 Month

24 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 248.67 USD with a low forecast of 204.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

9 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

204.00

Averages

248.67

High

289.00

Current: 0.000

Low

204.00

Averages

248.67

High

289.00

UBS

Neutral

initiated

$220 -> $240

2026-01-07

New

Reason

UBS

Price Target

$220 -> $240

2026-01-07

New

initiated

Neutral

Reason

UBS assumed coverage of AbbVie with a Neutral rating and price target of $240, up from $220. The firm sees a balanced risk/reward for the shares with competition emerging for the company's blockbuster immunology drugs Skyrizi and Rinvoq in 2026 and 2027. It views AbbVie as fairly priced at current levels.

BofA

Neutral

downgrade

$248 -> $233

2025-12-15

Reason

BofA

Price Target

$248 -> $233

2025-12-15

downgrade

Neutral

Reason

BofA lowered the firm's price target on AbbVie to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees "a relatively clean setup" for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.

Morgan Stanley

Overweight

maintain

$261 -> $269

2025-12-12

Reason

Morgan Stanley

Price Target

$261 -> $269

2025-12-12

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on AbbVie to $269 from $261 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Hold

Buy

upgrade

$225 -> $265

2025-12-10

Reason

HSBC

Price Target

$225 -> $265

2025-12-10

upgrade

Hold

Buy

Reason

HSBC upgraded AbbVie to Buy from Hold with a price target of $265, up from $225. The company is seeing growth momentum and its execution should remain solid, the analyst tells investors in a research note. The firm believes Tremfya competition to Skyrizi is unlikely to be a meaningful risk for AbbVie. HSBC says the company's upcoming pipeline readouts are undervalued at current share levels.

Scotiabank

Outperform

initiated

$280

2025-11-12

Reason

Scotiabank

Price Target

$280

2025-11-12

initiated

Outperform

Reason

Scotiabank initiated coverage of AbbVie with an Outperform rating and $280 price target.

H.C. Wainwright

Patrick Trucchio

Buy

downgrade

$40 -> $35

2025-11-10

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$40 -> $35

2025-11-10

downgrade

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio lowered the firm's price target on GH Research (GHRS) to $35 from $40 and keeps a Buy rating on the shares. Competitive momentum in short-acting psychedelics, led by advancing programs such as Atai Beckley's (ATAI) BPL-003 and AbbVie's (ABBV) GM-2505, combined with the ongoing FDA hold, led the firm to fine-tune its expected GH001 launch timing and peak share in treatment-resistant depression, resulting in a revised price target. However, it continues to view GH001 as a leading asset within the short-duration psychedelics space and notes that its revised target still represents "robust upside potential."

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 16.63, compared to its 5-year average forward P/E of 12.96. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.96

Current PE

16.63

Overvalued PE

15.85

Undervalued PE

10.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.04

Current EV/EBITDA

14.93

Overvalued EV/EBITDA

14.06

Undervalued EV/EBITDA

10.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.85

Current PS

6.25

Overvalued PS

5.73

Undervalued PS

3.98

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABBV News & Events

Events Timeline

No data

News

9.0

01-06NASDAQ.COM

PinnedAbbVie Receives Health Canada Approval for MAVIRET to Treat Hepatitis C, Enhancing Patient Treatment Timeliness

5.0

13:05 PMFool

Red Spruce Capital Sells 185,157 Shares of Invesco BulletShares ETF for $3.65 Million

7.5

01-06Benzinga

Health Care ETFs Surge as Demand for Weight-Loss Drugs Increases

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 229.23 USD — it has increased 2.37 % in the last trading day.

What is AbbVie Inc (ABBV)'s business?

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

What is the price predicton of ABBV Stock?

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 15.78B USD, increased 9.10 % YoY.

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 0.10 USD, decreased -88.64 % YoY.

What changes have occurred in the market's expectations for AbbVie Inc (ABBV)'s fundamentals?

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 55000 emplpoyees as of January 07 2026.

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 395.77B USD.

ABBV

Overview

Forecast

Valuation

Earnings

ABBV

Overview

Forecast

Valuation

Earnings

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ABBV News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

What is AbbVie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for AbbVie Inc (ABBV)'s fundamentals?

How many employees does AbbVie Inc (ABBV). have?

What is AbbVie Inc (ABBV) market cap?